Cambrex
East Rutherford, NJ
Program data pending ClinicalTrials.gov matching
—
Not Assessed
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesSmall Molecule API, Peptide API, HPAPI, Controlled Substances, Continuous Flow Chemistry
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
—
Insufficient financial data. Score requires company profile or SEC filings.
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
—
Insufficient capacity data. Score requires company profile with manufacturing site information.
Recent Press10 articles
Broad modality coverage (5 modalities)
Recent News 10 articles
Cambrex Unveils $120 Million Investment to Expand API Manufacturing and Strengthen U.S. Drug Supply Resilience - PR Newswire
PE firm to buy Cambrex for $2.4B amid flurry of CDMO acquisitions - BioPharma Dive
Cambrex unveils $120m investment to expand API manufacturing and strengthen US drug supply resilience - Manufacturing Chemist
Permira looks to launch $4B sale of CDMO Cambrex: FT - Fierce Pharma
Cambrex to drop $120M to expand US operations amid industry's breakneck onshoring drive - Fierce Pharma
Alcami Brings Third Sterile Fill-Finish Line Online, Expanding Clinical-to-Commercial Capacity - Pharmaceutical Commerce
Eli Lilly collaboration to accelerate biotech manufacturing - European Pharmaceutical Review
U.S. pharma plants soar in value as tariffs spur Celltrion's acquisition bid - 조선일보
Cambrex Commits $120 Million to Grow US API Manufacturing - Pharmaceutical Commerce
Cambrex Announces Strategic Agreement with Lilly to Support Biotech Collaborator Manufacturing - BioSpace
Represent this organization? Contact us to verify or update this profile.